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ARTICLE INFO  ABSTRACT 
 
 
Vitamin D is produced through the cutaneous transformation of 7-dehydrocholesterol by UVB-
irradiation with multiple neurotrophic and neuroprotective functions, while regulating calcium-
mediated neuronal excitotoxicity. Vitamin D acts mainly through binding to intracellular Vitamin 
D receptor (VDR) with a possible involvement of vitamin D receptor (VDR) and vitamin D-
binding protein (VDBP). This is a review of evidence for the aetiological role of vitamin D in 
dementias and other neurological disorders. There is contradictory evidence regarding vitamin D 
supplementation in the prevention of dementia progression. Adding vitamin D to the standard 
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Vitamin D is a secosteroid hormone with a common synthetic 
pathway with cholesterol. It is produced endogenously through 
the transformation of 7-dehydrocholesterol by UVB-irradiation 
or obtained via absorption (Boucher, 2012). The mechanism of 
action of vitamin D occurs mainly through binding to 
intracellular vitamin D receptor (VDR), where vitamin D 
regulates the phenotypic stability of cell signalling components 
such as Ca2+ and reactive oxygen species (ROS) (Berridge. 
2016,Tong et al. 2018). Vitamin D influence almost all 
metabolic processes such as apoptosis, inflammatory 
processes, differentiation and could be involved in the ageing 
process (Kubis and Piwowar. 2015, Anastasiou et al. 2014). 
In the nervous system, vitamin D is involved in calcium-
mediated neuronal excitotoxicity regulation, oxidative stress 
reduction, and neurotrophic factors induction (Mpandzou et al. 
2016). Vitamin Dinhibits cytokines involved in T-lymphocytes 
differentiation and pro-inflammatory cytokine production, 
while regulating T-regulatory development (Speer. 2013). 
Vitamin D actions within the cell include control of pathways 
such as intracellular calcium, PKA, and PI3K  
 
signalling,  improved amyloid-β (Aβ)peptides phagocytosis by 
macrophages and inhibited Aβ-induced apoptosis in 
Alzheimer's disease (Mizwicki et al. 2013). The world-wide 
incidence of vitamin D deficiency is high especially in the 
elderly (Alhamad et al. 2014). Vitamin D deficiency is 
common in psychogeriatric patients and in chronic diseases 
(Muscogiuri et al. 2017) and in cerebral small vessel disease 
(Carluccio et al. 2017).  Alzheimer’s Disease (AD) is the most 
common form of dementia affecting about 46 million people 
worldwide and is characterized by progressive loss of memory, 
language and cognition (Wood and Gupta. 2015). AD is 
characterized pathologically by extracellular amyloid plaques 
composed of aggregated Aβ peptides and intracellular 
neurofibrillary tangles containing the microtubule-associated 
protein tau (Grimm et al., 2016). AD progression is associated 
with oxidative/nitrosative stress, mitochondrial damage, 
neuroinflammation &finally neuronal cell death (Pretorius et 
al. 2016; Di Domenico et al. 2015). There are several risk 
factors related to AD as hypercholesterolemia and type 2 
diabetes, but the role of pro-inflammatory cytokines and 
vitamin D is not fully understood (Chakrabarti et al. 2015).  
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The current pharmacological treatment for AD includes acetyl 
cholinesterase and/or memantine to slow the disease 
progression and control behavioural changes. In this review, 
we aim to examine the aetiology of hypovitaminosis D in 
dementia progression and the possible future role of vitamin 
Din the pharmacological management of dementia. 
 
Vitamin D and Dementia: What is the Evidence?  
 
Animal studies suggests that vitamin D has a role in the 
slowness of dementia. This was evidenced from the molecular 
changes after 5 months of vitamin D supplementation in 
transgenic AD model mice brains. These changes resulted in 
improved learning and memory performance (Landel et al. 
2016). Mice fed on a diet supplemented with mushrooms - a 
convenient dietary source of vitamin D, displayed reduced 
amyloid plaque and elevated interleukin-10 (Bennett et al. 
2013).Further animal studies suggested that vitamin D was 
linked to up-regulation of neurotrophic factors (Peterson et al. 
2013). Moderate vitamin D hypovitaminosis was associated 
with an increase in the Aβ (Grimm et al. 2014). In Humans, 
Hypovitaminosis D could be associated with brain changes and 
cognitive decline (Annweiler et al. 2016). There is some 
evidence of vitamin D deficiency in Other neurological 
diseases such as multiple sclerosis (MS), Parkinson's disease 
(PD) in addition to AD (Mpandzou et al. 2016). Another long 
follow up study (6-years) confirmed the association of vitamin 
D deficiency and the risk of all-cause dementia (Littlejohns et 
al. 2014). In 666 non-demented participants followed for 
12 years, lower vitamin D levels were associated with a higher 
risk of dementia (Amadieu et al. 2017). In a study of 498 
community-dwelling women, 70 of them later developed AD 
(Annweiler et al. 2012c). The mean levels of vitamin D were 
significantly different for AD patients in comparison to healthy 
controls And mild cognitive impairment (MCI) patients (Yesil 
et al. 2015). Vitamin-D sufficient patients have shown a higher 
mini mental state examination (MMSE) scores (Oudshoorn et 
al. 2008). In another study for elderly, vitamin D deficiency 
was associated with declining MMSE scores (Toffanello et al. 
2014). 
 
In other types of dementias, vitamin D deficiency (<12 ng/ml) 
was associated with 2.2-fold increase in odds of vascular 
dementia (VaD) (Annweiler et al. 2011b, Prabhakar et al. 
2015) and impairment in working memory/executive 
functioning (Pettersen et al. 2014). High dose of vitamin D 
supplementation could enhance performance in some aspects 
of Dementia such as visual memory and Paired Associates 
Learning Task (Pettersen. 2017) . A large US study found an 
association between severe vitamin D deficiency and visual 
memory decline but not verbal memory decline (Kuzma et al. 
2016). In a study with more than 380 participants, rates of 
decline in episodic memory and executive function among 
vitamin D-deficient were greater (Miller et al. 2015). Vitamin 
D deficiency was shown to be associated with neuronal 
disruption primarily in frontal regions (Moon et al. 2015b). 
Deficits in specific cognitive domains such as executive 
functions, wordlist encoding, and visual memory (encoding 
and recall) were significantly associated with low vitamin D 
concentration in a study of more than 1000 individuals (Nagel 
et al. 2015). Furthermore, in 1,990 aging adults, vitamin D 
intake was positively associated with short-term memory 
improvement (Andreeva et al. 2014). Low vitamin D and 
cognitive decline was observed in multiple ethnic groups 
(Vedak et al. 2015).  
Higher serum 25(OH) D concentrations showed a reduced risk 
of dementia in a long follow up study (17-years) of more than 
5000 individuals free of dementia at baseline (Knekt et al. 
2014). Vitamin D deficiency was also associated with lower 
hippocampal volumes and poorer neuropsychological function 
(Karakis et al. 2016) with higher risk of cognitive decline in 
the elderly with deficient vitamin D levels (Dickens et al. 
2011). New insights in dementia pathophysiology highlighted 
the possible role of increased intracellular free calcium in AD 
nerve cells with neurofibrillar tangles with augmentation of 
short chain Aβ production (Fujita. 2004).Studies showed that 
vitamin D prevents Aβ-induced calcium elevation affecting 
nerve growth factor (NGF) release in cortical neurons (Gezen-
Ak et al. 2014). Defective phagocytosis of soluble Aβ by AD 
macrophages could be recovered by vitamin D and is blocked 
by the Vitamin D Receptor; (VDR) antagonist (Mizwicki et al. 
2012).Vitamin D supplements could enhance toll-like 
receptors, modulate vascular endothelial factor expression and 
angiogenin (Lu'o'ng and Nguyen. 2013).  
 
Vitamin D level and the Cerebrospinal fluid (CSF) in 
Alzheimer’s Disease: Vitamin D concentration and CSF 
acetyl cholinesterase (AChE) were both decreased in the CSF 
of AD. In AD patients, CSF AChE activity correlated 
positively with CSF levels of total tau (r = 0.44) and 
phosphorylated tau protein (r = 0.50) (Johansson et al. 2013). 
A positive correlation was found between vitamin D and 
cerebral blood flow in AD patients left cortex (Farid et al. 
2012). In a study of 75 patients (29 with subjective cognitive 
impairment, 28 with MCI, 18 with AD), higher vitamin D 
levels were related to higher concentrations of CSF Aβ and 
bigger brain volumes (Hooshmand et al. 2014). 
 
Does Vitamin D have a role in Dementia Treatment? 
 
Vitamin D supplementation caused significant improvement in 
the cognitive performance in subjects with MMSE score < 24 
(Gangwar et al. 2015) and was associated with less 
progression from mild AD to severe (5.4 ± 0.4 years vs. 4.4 ± 
0.16 years) (Chaves et al. 2014). Vitamin D supplement added 
to memantine was found to have a neuroprotective effects in a 
study for 58 patients (Lemire et al. 2016). This was found to 
be related to preventing A β and glutamate neurotoxicity 
(Annweiler et al. 2014). This study was replicated confirming 
that adding vitamin D to memantine was superior over 
medications given separately. Participants on the combined 
treatment showed increased MMSE score by 4.0 ± 3.7 points, 
while taking memantine or vitamin D alone did not show an 
increase in MMSE (Annweiler et al. 2012b). A new 
agentdenosomin (an artificial inducer of neurite elongation) 
affects axonal extension via a vitamin D-membrane-
associated, rapid response steroid-binding protein pathway in 
Aβ-damaged neurons (Sugimoto et al. 2015). Bexarotene, a 
Retinoid X receptors (RXRs) agonist used for the treatment of  
cutaneous T-cell lymphoma, was found to be useful in 
AD(Yamada and Kakuta. 2014). 
 
Vitamin D receptor (VDR) and Vitamin D-binding protein 
(VDBP): Receptors for 1,25-dihydroxyvitamin D3, the 
metabolite of vitamin D are widely expressed in human brain. 
1,25-dihydroxyvitamin D3 was found to increase 27 genes 
mRNA levels by at least 1.9 fold, including17 genes related to 
neurodegenerative and psychiatric diseases (Nissou et al. 
2013). AD genetic mapping identified loci in chromosome 
12q13 encompassing the VDR gene. VDR levels were reduced 
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in AD hippocampal pyramidal cells (Sutherland et al. 1992) 
and VDR gene polymorphisms contributed to aging (Gussago 
et al. 2016). Two polymorphisms with linked alleles, Apa1 T 
and Taq1 G, were associated with risk of AD and possible 
interactions with other genes involved in the regulation of 
inflammation (Lehmann et al. 2011, Laczmanski et al. 2015). 
Furthermore, Single nucleotide polymorphisms (SNPs) in its 3' 
end was associated with PD and AD (Butler et al. 2011) 
through VDR role in reducing cerebral Aβ peptides 
particularly in the hippocampus (Durk et al. 2014). VDR SNPs 
in702 participants were associated with a decline in category 
fluency (Beydoun et al. 2012) by affecting vitamin D binding 
to its receptor resulting in neuronal damage (Gezen-Ak et al. 
2007). VDR polymorphisms were also associated with an 
increase in white matter lesions (James et al. 2011), while 
VDR over expression suppressed APP transcription in 
neuroblastoma cells (Wang et al. 2012). VDR is used in a 
panel of 8 CSF proteins effective at identifying PD and AD 
(Zhang et al. 2008). The biologically active 1,25-
dihydroxyvitamin D interacts with VDR to increase the 
efficiency of intestinal calcium and phosphate absorption. The 
final converting enzyme and VDR are found throughout the 
human brain, with higher intake of vitamin D associated with 
lower Aβ load (Mosconi et al. 2014).  AD has been related to 
an increase of incompetent memory T cells and defective 
clearance of Aβ by macrophages (Fiala. 2010). Vitamin D 
binding protein (VDBP) reduced Aβ aggregation in vitro, 
prevented Aβ-mediated cell line death and decreased Aβ-
induced synaptic loss in hippocampus (Moon et al. 2013).  
VDBP a multifunctional protein, acts as an Aβ scavenger and 
its serum levels were inversely related to cognitive 
performance (Bishnoi et al. 2015) and decreased in Mild 
cognitive impairment (Muenchhoff et al. 2015).  
 
Vitamin D role in Mild Cognitive Impairment (MCI) and 
Neurological Disorders: Vitamin D deficiency at baseline 
was independently associated with the progression of MCI 
(Moon et al. 2015a). In a study with more than 1300 
participants, lower vitamin D levels led to more pronounced 
cognitive decline (Perna et al. 2014) and increased serum 
vitamin D concentration was associated with a lower risk of 
MCI (Annweiler et al. 2012a). A potent vitamin D analogue – 
calcipotriol could suppress calcium-dependent α-synuclein 
aggregation in Parkinson’s Disease (PD)(Rcom-H'cheo-
Gauthier et al. 2017) and higher vitamin D concentrations 
were associated with better performance in neuropsychiatric 
tests (Peterson et al. 2013). Vitamin D deficiency is associated 
with a higher relapse rate, a higher number of MRI lesions and 
worse cognitive performance in Multiple Sclerosis (MS). In 35 
adults with relapsing-remitting MS, vitamin D level was 
positively associated with performance on immediate and 
delayed recall of the Rey Complex Figure Test-nonverbal 
long-term memory performance but not associated with mood, 
intelligence, or verbal memory performance (Koven et al. 
2013). There is evidence for vitamin D deficiency in the 
pathophysiology of epilepsy (Hollo et al. 2014) and ischemic 
stroke (Thouvenot and Camu. 2013). 
 
What is the Evidence against the role of Vitamin D in 
Dementias? 
 
Vitamin D deficiency has been linked with cognitive decline in 
several studies. But other research challenged the role of 
vitamin D in dementias. Most Dementia trials look specifically 
at the global improvement in cognition and behaviours. No 
associations were found between vitamin D levels and the 
global cognitive function in a cohort of elderly psychiatric 
inpatients (Lapid et al. 2013) and in another large cohort with 
18 y follow-up, plasma vitamin D was not associated with 
cognitive outcomes (Olsson et al. 2017). Another follow-up 
study showed no correlation between 25(OH) D and 
depression/or dementia (Cartier et al. 2017). Studies of 
visuoconstructional abilities, visual memory and processing 
speed did not support a role of vitamin D level (Overman et al. 
2016) Serum 25(OH) D status was not significantly associated 
with neuroimaging abnormalities (Littlejohns et al. 2016) and 
there were no significant association between lower levels of 
vitamin D with lower cognitive scores at baseline, change in 
scores over time or dementia risk(Schneider et al. 2014). No 
association between vitamin D and plasma Aβ levels in 1,219 
cognitively healthy elderly was found (Gu et al. 2012). 
Furthermore, there are concerns about the lack of consensus 




Ageing is considered the most significant risk factor for 
Dementia.AD is characterized by an activation of the cerebral 
immune system, glutamatergic excitotoxicity that results in 
neuronal death and a decrease in brain cholinergic activity. 
The currently available medications; acetyl cholinesterase 
inhibitors and memantine are used for symptomatic treatment, 
slowness of AD progression and controlling behavioural 
changes (Annweiler and Beauchet. 2012). Dietary products 
rich in vitamins such as fruits, vegetables, grains and fish were 
suggested to be protective against AD, where diet increasing 
the risk include meat, and high-fat dairy products (Grant. 
2016). Vitamin D represents a promising therapeutic tool for 
reducing cytokine-mediated neuroinflammation in AD 
(Magrone et al. 2012), The deficiency of vitamin D is a 
worldwide significant problem with an estimates 1 billion 
affected (Iwamoto et al. 2012).The older population are at 
particularly risk due to decreased cutaneous synthesis &dietary 
intake (Schlogl and Holick. 2014) . It was shown that 2/3 of 
over 65 years have insufficient serum vitamin D (Ribera 
Casado. 2012). Vitamin D deficient individuals, especially 
elderly could be candidates for vitamin D supplementation 
(Keeney and Butterfield. 2015). Cognitive impairment in older 
people is an established risk factor for falls and AD individuals 
are at higher risk for fractures (Casas Herrero et al. 2011). The 
role of vitamin D could provide added protection infractures 
and dementia at the same time (Hanyu. 2015). 
 
Hypovitaminosis D (< or =20 ng/mL) was associated with 
more than twice the odds of all-cause dementias (odds ratio 
[OR] = 2.3) and in particular AD (OR = 2.5) (Buell et al. 
2010) and also associated with brain structural abnormalities 
(Berridge. 2015) and cerebrovascular events such as large 
vessel infarcts and fatal stroke (Soni et al. 2012). Experts 
believe that hypovitaminosis D increases the risk of cognitive 
decline (Annweiler et al. 2016, Manzo et al. 2016). Animal 
studies show that vitamin D supplementation is protective and 
enhances learning and memory performance (Annweiler. 
2016). Further research supported these opinions (van der 
Schaft et al. 2013); however, these studies were mostly 
observational (Sommer et al. 2017), and other studies failed to 
associate increased vitamin D levels with improved cognitive 
outcomes (Landel et al. 2016a). There are several proteins at 
the molecular level linking AD to vitamin D levels such as 
VDR, apolipoprotein E, L-type voltage-sensitive calcium 
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channels, nerve growth factor and nitric oxide synthase 
(Lu'o'ng and Nguyen. 2013). Future combination of drugs 
therapies such as memantine with vitamin D could be 
considered in the management of Dementia and other 
neurodegenerative diseases (Annweiler et al. 2011a). Vitamin 
D combined with resveratrol (Nutritional compound with 
neuroprotective effects) showed a reduction in soluble Aβ and 
phosphorylation of tau in mice hippocampus (Cheng et al. 
2017). It appears there is evidence for vitamin D supplement 
on several domains in dementia, but the global clinical 
improvement is still not fully understood. Further studies, 
randomized trials and medications licensing approvals are 
needed to reveal the full clinical benefit of vitamin D as a 
treatment or an augmentation in neurological conditions 
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